HANK & LIN'S GROUP

¹⁸F-AlF-P16-093

1. Zhao, Ruiyue, et al. "First-in-human study of PSMA-targeting agent,[¹⁸F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients." European Journal of Nuclear Medicine and Molecular Imaging51 (2024): 1753-176
   
2. Zhao, Ruiyue, et al. “Determining the optimal pharmacokinetic modelling and simplified quantification method of [¹⁸F]AlF-P16-093 for patients with primary prostate cancer (PPCa)”.European Journal of Nuclear Medicine and Molecular Imaging

   51(2024):2124–2133

3. Alexoff, D., Choi, S.R., Ploessl, K.et al.Optimization and scale up of production of the PSMA imaging agent [¹⁸F]AlF-P16-093 on a custom automated radiosynthesis platform. EJNMMI radiopharm. chem.9, 15 (2024).
4. Zha, Z., Choi, S.R., Ploessl, K., Alexoff, D., Zhao, R., Zhu, L. and Kung, H.F., "Radiolabeling optimization and preclinical evaluation of the new PSMA imaging agent [¹⁸F]AlF-P16-093." Bioconjugate Chemistry 32.5 (2021): 1017-1026.

Meeting Abstracts：

1. Alexoff, David, Seokye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu, and Hank Kung. "Large scale production of the PSMA imaging agent [¹⁸F]AlF-P16-093 on a custom automated radiosynthesis platform." Journal of Nuclear Medicine 65 (supplement 2), (2024): 241116.
2. Ke M, Zhao R, Lv J, Alexoff D, Ploessl K, Zhu L, Kung HF, Wang X. Head-to-head comparison of [¹⁸F]AlF-PSMA-093 and [¹⁸F]AlF-PSMA-BCH PET/CT in prostate cancer diagnosis. Journal of Nuclear Medicine 65 (supplement 2), 241116